Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo
Journal of Medicinal Chemistry · 25.05.2023 · 66 (10) · 6631-6651
DOI: 10.1021/acs.jmedchem.2c02032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.05.2023. Verfasst von Baohua Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, Central University Basic Research Fund of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
The estrogen receptor (ER) is a well-established target for endocrine therapies of ER-positive breast cancer (ER+ BC), but endocrine resistance limits the efficacy of clinical drugs. Using proteolysis targeting chimera (PROTAC) technology to degrade ERα may be an effective alternative to endocrine therapies. Herein, we disclose a novel series of potent and selective ERα PROTACs based on an oxabicycloheptane sulfonamide (OBHSA) scaffold, with no associated ERβ degradation. These PROTACs showed significant antiproliferation and ERα degradation activities against a broad spectrum of ER+ BC cells including tamoxifen-resistant and ERα mutant cell lines. Genomics analysis confirmed that these PROTACs inhibited the nascent RNA synthesis of ERα target genes and impaired genome-wide ERα binding. Compound ZD12 exhibited excellent antitumor potency and ERα degradation activity in both tamoxifen-sensitive and -resistant BC mice models, which are superior to fulvestrant. This study demonstrates the potential of these PROTACs as novel drug candidates for endocrine-resistant BC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
- Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China.
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan 430072, China.
- Frontier Science Center for Immunology and Metabolism, State Key Laboratory of Virology, Provincial Key Laboratory of Developmentally Originated Disease, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (…
ORCID-Profile: Hai-Bing Zhou
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Central University Basic Research Fund of China
- National Natural Science Foundation of China
Zitieren
APA
Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., Zhou, H. B., & Dong, C. (2023). Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo. Journal of Medicinal Chemistry, 66(10), 6631-6651. https://doi.org/10.1021/acs.jmedchem.2c02032
Vancouver
Xie B, Yin Z, Hu Z, Lv J, Du C, Deng X, et al. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo. Journal of Medicinal Chemistry. 2023;66(10):6631-6651. doi:10.1021/acs.jmedchem.2c02032
BibTeX
@article{Xie2023,
author = {Xie, Baohua and Yin, Zhinang and Hu, Zhiye and Lv, Junhui and Du, Chuanqian and Deng, Xiangping and Huang, Yuan and Li, Qiuzi and Huang, Jian and Liang, Kaiwei and Zhou, Hai-Bing and Dong, Chune},
title = {Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {10},
pages = {6631--6651},
doi = {10.1021/acs.jmedchem.2c02032}
}
EUVIMED